Cytogen, Inc. (217330.KQ)

11,580.00 -250.00 (-2.11%) At close: 03:30PM KST

Cytogen, Inc.

SK V1 GL Metrocity
A, 8th Floor 128, Beobwon-ro Songpa-gu
Seoul 05854
South Korea
82 2 6925 1070
https://www.cytogenlab.com

Sector(s): 
Industry: 
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Byung-Hee Jeon	CEO & Director	N/A	N/A	1959

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.

Description

Cytogen, Inc., a biotechnology company, develops and sells CTC (circulating tumor cell) enrichment and downstream systems to treat cancer in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immune florescence staining systems; and cell image analyzers, which help capture and analyze multi-fluorescence images with multi-channel image sensors and cameras. It also provides time laps incubators, which help monitoring cell growth and capture cell images from the cell culture plates. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was incorporated in 2010 and is headquartered in Seoul, South Korea.

Corporate governance

Cytogen, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.